title: Thrombocytosis and hematocrit as prognostic factors in renal carcinoma.
abstract: OBJECTIVE
  To examine the connection between preoperative thrombocytosis and hematocrit and survival in a group of patients operated for renal cell  carcinoma.
  
  
  METHODS
  Retrospective study with descriptive and statistical analysis of 139 patients with renal cell carcinoma treated surgically over the last 4  years in our Urology clinical unit. 116 (83,45%)were diagnosed at a localized clinical stage, whereas 23 (16,54%)  presented as locally advanced or metastatic disease. We collected data about survival and time on surveillance, imaging and histological characteristics  of the tumor and analytical parameters. Data were analyzed by the SPSS statistical software.
  
  
  RESULTS
  The average platelet count and hematocrit before surgery were 260,930 cells/mm3 and 41.10%, respectively. We found a statistical  correlation between platelet count at the time of diagnosis and survival. Patients with platelet counts higher than 350,000 cells/mm3 had  a poor survival (OR: 2.94; CI 95% 1.04- 8.27). We also found that patients with high hematocrit at diagnosis presented a  lower risk of death   (OR: 0.92; CI 95% 0.85-  0.99). The global survival at the end of the study was 88.4%. Multivariate analysis  did not show any significant  result  because of the low number of deaths.
  
  
  CONCLUSIONS
  The presence of high platelet count or low hematocrit correlate with poor survival in a group of surgically treated renal cell  carcinoma patients. Nevertheless more studies with longer surveillance and higher number of patients are needed.
authors.affiliation: Clinical Management in Urology and Nephrology Unit, University Hospital Virgen del Rocio, Sevilla, Spain. carlosjavierhuerta@hotmail.com
authors.forename: Carlos Javier Ortega
authors.initials: CJ
authors.lastname: Seda
authors.forename: Alberto San Juan
authors.initials: AS
authors.lastname: Salas
authors.forename: Cristina García
authors.initials: CG
authors.lastname: Sánchez
authors.forename: José María Lozano
authors.initials: JM
authors.lastname: Blasco
authors.forename: Ignacio Osman
authors.initials: IO
authors.lastname: García
authors.forename: José Manuel Conde
authors.initials: JM
authors.lastname: Sánchez
authors.forename: Carmen Belén Congregado
authors.initials: CB
authors.lastname: Ruíz
authors.forename: Salvador Mármol
authors.initials: SM
authors.lastname: Navarro
authors.forename: Rafael Antonio Medina
authors.initials: RA
authors.lastname: López
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000150:complications* / Q000401:mortality / Q000601:surgery; D005260:Female; D006400:Hematocrit; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000150:complications* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013922:Thrombocytosis / Q000150:complications*